Duncan Bucknell

An extremely useful strategy for companies seeking to avoid patent infringement, is to precipitate patent litigation by commencing court proceedings requesting a declaration from the court that the patent is either...

The recent article – ‘A Patent Is Worth Having, Right? Well, Maybe Not‘ (New York Times) has created a furore in the IP world. It reports the findings of two Economics...

I recently put together a pilot study to test some views on the factors which affect success in the ongoing war between ‘innovator’ and ‘generic’ companies. In this, the first in...

I recently put together a pilot study to test some views on the factors which affect success in the ongoing war between ‘innovator’ and ‘generic’ companies. In this, the first in...

On 10 July 2007, the Dublin High Court held that Ranbaxy’s product infringes the Pfizer Base patent.Same result, different country (see the scorecard on this site for details). [Note, though that...

The Carvedilol story took another interesting turn recently, when on 21 June, Teva sued 7 pharmaceutical companies (Dr Reddy’s, Ranbaxy, Lupin, Orchid, Cadilla, USV & Warnbury) for infringement of 4 of...

I have been lucky enough to have some great discussions with some fantastic people in the USA and UK over the past couple of weeks. One of my pet topics is...

In the latest round of the fight in India over Glivec, Novartis challenges rejection of its Glivec crytalline form patent by the Indian Patent Office on two grounds. (1) the patent...

The first-instance judgment in the Australian part of the global Lipitor patent dispute was handed down earlier today (20 December 2006). Click here to go to the judgment. In essence, as...

This one’s succinct but very important for those interested in the interplay between IP strategy and government regulatory control or pharmaceuticals in the USA. The broad take-home is — if government...